SCHEMBL852436

SCHEMBL852436

CS(=O)(=O)OB(O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ORAI1 Q96D31 3/20 0.41
ORAI2 Q96SN7 3/20 0.41
ORAI3 Q9BRQ5 3/20 0.41
TRPV6 Q9H1D0 3/20 0.41
ENPP2 Q13822 2/20 0.41
PCSK9 Q8NBP7 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA5A P35218 2/20 0.41
CA7 P43166 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5B Q9Y2D0 2/20 0.41
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTR6 P50406 1/20 0.36
PSIP1 O75475 1/20 0.35
GAA P10253 1/20 0.35
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
KEAP1 Q14145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289766 0.82 PSIP1 (0.43) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL6647498 0.80 ORAI1 (0.45) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL15924441 0.79 CA1 (0.43) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL1742560 0.79 L3MBTL1 (0.38) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL4445533 0.78 HTR6 (0.39) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL1158666 0.75 KEAP1 (0.39) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL7377059 0.74 MAPT (0.37) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL3403354 0.73 ORAI1 (0.35) ORAI1ORAI2ORAI3TRPV6ENPP2
SCHEMBL27896282 0.72 PGR (0.37) CA4SMN1; SMN2CA1CA2KEAP1
SCHEMBL29216494 0.72 CA4 (0.34) ORAI1ORAI2ORAI3TRPV6ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
US-20240301130-A2 STORAGE STABLE EPOXY RESIN COMPOSITION (II) ALZCHEM TROSTBERG GMBH (DE) 2024-09-12 US disclosed
US-20240059830-A1 STORAGE STABLE EPOXY RESIN COMPOSITION (II) ALZCHEM TROSTBERG GMBH (DE) 2024-02-22 US disclosed
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-06-15 US disclosed
EP-4178965-A1 BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION Pfizer Inc. (US) 2023-05-17 EP disclosed
EP-4118136-A1 DYNAMIC COVALENT HYDROGELS, PRECURSORS THEREOF AND USES THEREOF Centre National de la Recherche Scientifique (CNRS) (FR) 2023-01-18 EP disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed
WO-2022008912-A1 BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION ReViral Limited (GB) 2022-01-13 WO disclosed
EP-3894398-A1 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Yuhan Corporation (KR) 2021-10-20 EP disclosed
WO-2020121261-A1 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-06-18 WO disclosed
WO-2006019833-A1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-02-23 WO disclosed
US-20060030596-A1 NF-kappaB inhibitors SMITHKLINE BEECHAM CORPORATION 2006-02-09 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
WO-2005087765-A1 LIGANDS OF FOLLICLE STIMULATING HORMONE RECEPTOR AND METHODS OF USE THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-09-22 WO disclosed
WO-2005049593-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-06-02 WO disclosed
EP-1416799-A4 METHODS AND COMPOSITIONS FOR TREATING FUNGAL INFECTIONS UNIV RAMOT (IL) 2004-11-10 EP disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed
EP-1416799-A1 METHODS AND COMPOSITIONS FOR TREATING FUNGAL INFECTIONS Ramot at Tel Aviv University Ltd. (IL) 2004-05-12 EP disclosed
WO-2003009689-A1 METHODS AND COMPOSITIONS FOR TREATING FUNGAL INFECTIONS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CDC37, ILK, PTMS ORAI1 4159/4885ORAI2 4627/4885ORAI3 4462/4885
US-20060030596-A1 NF-kappaB inhibitors NFKBIA, IKBKB, IKBKG ORAI1 3690/4885ORAI2 3123/4885ORAI3 3237/4885
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 ORAI1 4394/4885ORAI2 4778/4885ORAI3 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.